BridgeMD
Effect of Cannabidiol on Muscle Mass and Mitochondrial Function in Head and Neck Cancer
EU CTIS ID: 2024-519637-32-00
What this study is testing
Improvement of muscle health assessed by muscle mitochondrial activity perioperatively by adding cannabidiol (CBD) to nutritional supplementation in head and neck cancer
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, larynx or prevalent lymphadenopathy) or high probability of squamous cell carcinoma of the head and neck according to the judgment of the investigator (without histological confirmation)
- Stage 2 or 3 nutritional risk according to the classification specific to this study (light to moderate nutritional risk)
- Consent to participate in the study
- For women of childbearing age: absence of current pregnancy and effective contraceptive method for the duration of treatment with CBD and up to 7 days after the end of treatment
- To have of a means of communication (mobile phone) to monitor tolerance and appetite while taking CBD
You likely can't join if
- History of severe heart failure, severe respiratory failure, severe renal failure, severe chronic obstructive pulmonary disease, uncontrolled insulin-dependent diabetes or uncontrolled coronary artery disease
- Addiction to other drugs or cannabis
- Pregnant and breastfeeding women
- Persons under curatorship, guardianship, protection of justice or deprived of liberty
- Age <18 years
- History of chemotherapy or radiotherapy for head and neck cancer
See the full eligibility criteria
- Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, larynx or prevalent lymphadenopathy) or high probability of squamous cell carcinoma of the head and neck according to the judgment of the investigator (without histological confirmation)
- Stage 2 or 3 nutritional risk according to the classification specific to this study (light to moderate nutritional risk)
- Consent to participate in the study
- For women of childbearing age: absence of current pregnancy and effective contraceptive method for the duration of treatment with CBD and up to 7 days after the end of treatment
- To have of a means of communication (mobile phone) to monitor tolerance and appetite while taking CBD
- History of severe heart failure, severe respiratory failure, severe renal failure, severe chronic obstructive pulmonary disease, uncontrolled insulin-dependent diabetes or uncontrolled coronary artery disease
- Addiction to other drugs or cannabis
- Pregnant and breastfeeding women
- Persons under curatorship, guardianship, protection of justice or deprived of liberty
- Age <18 years
- History of chemotherapy or radiotherapy for head and neck cancer
- Malnutrition prior to the onset of head and neck cancer
- Morbid obesity
- Absence of nutritional risk (grade 1) or severe nutritional risk requiring urgent renutrition (grade 4) during the nutritional assessment
- History of epilepsy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.